A daily pill that targets a once-"undruggable" cancer mutation is showing results doctors are calling the biggest leap forward in pancreatic cancer treatment in decades, with tumors shrinking or disappearing in the majority of patients tested in early trials.
In the phase I/II trial, tumors stopped growing in 90% of the 61 participants with newly diagnosed, advanced pancreatic cancer that had already spread elsewhere in the body. Just over 60% saw their tumors shrink or disappear outright, and for roughly 8% of patients — about one in 12 — cancer became undetectable on CT scans after treatment with the drug, daraxonrasib, combined with standard chemotherapy. The results were presented this week to oncologists at the EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.
"What this new drug has done is it's found a way of drugging the undruggable," said Dr. Sam Godfrey of Cancer Research UK, which called the results "the biggest leap forward in decades" for pancreatic cancer patients. "We are finally seeing progress in pancreatic cancer which is so long overdue."
A notoriously hard cancer to treat
Pancreatic cancer has the lowest survival rate of any common cancer, and chemotherapy alone typically shrinks tumors only modestly before the disease returns. Most patients with advanced disease survive months rather than years. The cancer kills roughly 53,000 people a year in the United States and about 10,200 annually in Britain, according to Cancer Research UK.
Daraxonrasib works by locking onto and shutting off RAS mutations that drive tumor growth in most pancreatic cancers — mutations long considered resistant to targeted drugs. The medication has already won approval in the United States for other indications. Because similar RAS mutations also appear in lung, ovarian and other cancers, researchers say the approach could eventually extend well beyond the pancreas.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center, who is involved in the trial, said the data so far point toward deeper and longer-lasting responses than earlier readouts showed. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival," Park said.
Caution ahead of longer follow-up
Doctors stressed the results should not be read as a cure. Patients were followed for roughly a year and a half on average, and researchers do not yet know how long the drug can keep the disease at bay in patients whose cancer has not returned. Prof. Elena Garralda, who chaired the conference session where the data were presented, said the findings were "exciting because they show the combined treatment could potentially significantly improve patients' overall survival," but added that longer studies are needed to confirm how durable the responses prove to be.
Godfrey agreed, cautioning that "cancer can come back" even when scans initially show no sign of disease. Larger confirmatory trials are now underway testing the drug as a first-line treatment, both alone and alongside chemotherapy.